Effect of depemokimab on asthma control and clinical outcomes: a systematic review and meta-analysis of randomized controlled trials
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Basım Tarihi: 2026
- Doi Numarası: 10.1080/17476348.2026.2688299
- Dergi Adı: EXPERT REVIEW OF RESPIRATORY MEDICINE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE, Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Anahtar Kelimeler: Asthma, depemokimab, eosinophilic asthma, meta-analysis, rhinosinusitis
- Gazi Üniversitesi Adresli: Evet
Özet
Introduction: Patients with eosinophilic asthma are at increased risk of poor asthma control despite optimized standard therapy. Depemokimab, a novel long-acting anti-interleukin-5 monoclonal antibody, has shown efficacy in reducing exacerbations; however, its effects across clinical outcomes have not been comprehensively synthesized. Methods:PubMed, Embase, Cochrane databases, and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) comparing depemokimab with placebo. Outcomes included Asthma Control Questionnaire-5 (ACQ-5), asthma exacerbation rate, quality of life assessed by St. George's Respiratory Questionnaire (SGRQ), and adverse events. Results were reported as mean differences (MDs) or incidence rate ratios (IRRs) with 95% confidence intervals (CIs), and heterogeneity was assessed using the I-2 statistic. Results: Four RCTs (n = 954) were included. Depemokimab did not significantly improve ACQ-5 (MD -0.30; 95% CI -0.92 to 0.32; I-2 = 73.6%; p = 0.23), but reduced exacerbation rates (IRR 0.47; 95% CI 0.36 to 0.59; I-2 = 0%; p < 0.001) and modestly improved SGRQ scores without reaching the MCID (MD -2.80; 95% CI -5.38 to -0.23; I-2 = 0.0%; p = 0.033). Safety was comparable to placebo. Conclusions: Depemokimab reduced exacerbations and had a comparable safety profile, but did not improve symptom control or achieve the MCID for health-related quality-of-life. Registration:The study protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD420261282685).